KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Asset Writedowns and Impairment (2022 - 2024)

Historic Asset Writedowns and Impairment for Nektar Therapeutics (NKTR) over the last 4 years, with Q2 2024 value amounting to $8.3 million.

  • Nektar Therapeutics' Asset Writedowns and Impairment fell 3716.33% to $8.3 million in Q2 2024 from the same period last year, while for Mar 2025 it was $8.3 million, marking a year-over-year decrease of 6301.84%. This contributed to the annual value of $8.3 million for FY2024, which is 7642.38% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Asset Writedowns and Impairment of $8.3 million as of Q2 2024, which was down 3716.33% from -$1.3 million recorded in Q4 2023.
  • Over the past 5 years, Nektar Therapeutics' Asset Writedowns and Impairment peaked at $57.3 million during Q2 2022, and registered a low of -$1.3 million during Q4 2023.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $9.4 million (2023), whereas its average is $13.7 million.
  • The largest annual percentage gain for Nektar Therapeutics' Asset Writedowns and Impairment in the last 5 years was 78058.33% (2023), contrasted with its biggest fall of 11795.58% (2023).
  • Nektar Therapeutics' Asset Writedowns and Impairment (Quarter) stood at $7.2 million in 2022, then crashed by 117.96% to -$1.3 million in 2023, then soared by 740.69% to $8.3 million in 2024.
  • Its Asset Writedowns and Impairment was $8.3 million in Q2 2024, compared to -$1.3 million in Q4 2023 and $10.6 million in Q3 2023.